Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
LMB Limbach Holdings Inc
CSCO Cisco Systems Inc
BIP Brookfield Infrastructure Partners LP
OGS ONE Gas Inc
GM General Motors Co
VCYT Veracyte Inc
BLUE bluebird bio Inc
GWPAX American Funds Growth Portfolio Class A
LIXTW Lixte Biotechnology Holdings Equity Warrants Exp 1st Jan 2025 *W EXP 01/01/2025
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Closing Price
$74.88
Day's Change
0.54 (0.73%)
Bid
--
Ask
--
B/A Size
--
Day's High
75.14
Day's Low
72.82
Volume
(Average)
Volume:
1,291,332

10-day average volume:
1,386,283
1,291,332

Company Profile

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Valuation Ratios

Price/Earnings (TTM)
17.70x
Price/Sales (TTM)
5.29x
Price/Book (MRQ)
4.26x
Price/Cash Flow (TTM)
16.57x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2022
Current Month
5.9M
Previous Month
4.5M
Percent of Float
2.69%
Days to Cover
5.3101 Days

Share Information

INCY is in a share class of common stock
Float
218.1M
Shares Outstanding
221.5M
Institutions Holding Shares
833
94.27%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Herve HoppenotChmn.
  • Christiana StamoulisCFO
  • Dashyant DhanakExec.VP
  • Maria E. PasqualeExec.VP
  • Jonathan Elliot DickinsonExec.VP

Address

Insider Trading

During the most recent quarter, 4M shares were bought, and 100K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.